{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
tyrosine
to a specific field?
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
18F-FET (18F-Fluoroethyl-L-tyrosine) is a radiolabelled amino acid. It penetrates the blood-brain barrier by a specific amino acid transport system. In the brain, it is taken up into upregulated tumoral cells but not incorporated into proteins. It is used as a biomarker for positron emission tomography for imaging brain tumors, where it has higher specificity than 18F-FDG.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Rociletinib is a novel, potent, small molecule, third generation TKI that irreversibly binds and inhibits EGFR with the common activating (L858R, Del19) and T790M resistance mutations. The proposed indication of rociletinib is for the treatment of patients with mutant EGFR NSCLC who have been previously treated with an EGFR-targeted therapy and have the T790M mutation as detected by an FDA approved test. The results from two Phase 2 studies show that rociletinib 625 mg BID treatment has a favorable benefit:risk profile in patients with recurrent T790M-positive mutant EGFR NSCLC based on clinically meaningful and durable responses and a well-established and acceptable safety profile in this patient population with terminal lung cancer. In May 2016, Clovis Oncology, Inc. announced it has terminated enrollment in all ongoing sponsored studies of rociletinib, including TIGER-3, after the company was notified at meeting with the FDA that it could anticipate receiving a Complete Response Letter (CRL) for the rociletinib NDA on or before the PDUFA date of June 28, 2016. Clovis has also withdrawn its Marketing Authorization Application of rociletinib with European regulatory authorities.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Oclacitinib (PF03394197) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family members by 50% at concentrations (IC50 's) ranging from 10 to 99 nM and did not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000 nm). Oclacitinib was most potent at inhibiting JAK1 (IC50 = 10 nm). Oclacitinib also inhibited the function of JAK1-dependent cytokines involved in allergy and inflammation (IL-2, IL-4, IL-6, and IL-13) as well as pruritus (IL-31) at IC50 's ranging from 36 to 249 nM. Oclacitinib as oclacitinib maleate is approved for control of pruritus associated with allergic dermatitis and control of atopic
dermatitis in dogs at least 12 months of age.
Status:
Possibly Marketed Outside US
Source:
Ritmonutra by Perkin, A.G.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Vitexin, identified as apigenin-8-C-β-D-glucopyranoside, is a flavonoid compound found in Anthurium versicolor, Ficaria verna Huds. (Ranunculaceae), Cucumis sativus L. (Cucurbitaceae), and Acer palmatum (Aceraceae). Vitexin is an active component of many traditional Chinese medicines. Vitexin has recently received increased attention due to its wide range of pharmacological effects, including but not limited to anti-oxidant, anti-cancer, anti-inflammatory, anti-hyperalgesic, and neuroprotective effects.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Radotinib (Supect) was developed and approved in Korea as a second-line Chronic Myeloid Leukemia treatment. The drug supresses cancer cells proliferation by inhibitiing BCR-ABL1 kinase which is a driver of Philadelphia chromosome-positive (Ph+) leukemia.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Dibromotyrosine is a brominated derivative of a natural amino acid tyrosine. In the human body, dibromotyrosine is produced by eosinophil peroxidase secreted from activated eosinophils. Dibromotyrosine is naturally produced by marine sponges. Dibromotyrosine is used in medicine for the treatment of functional hyperthyroidisms. It acts by competing with iodination of tyrosines, thus reducing the active form of the thyroid hormones. Dibromotyrosine also appears to maintain the ability to control TSH production through negative feedback on the pituitary gland, reducing the biological activity of the thyroid. Dibromotyrosine is marketed in Italy under tradename Bromotiren.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Diiodotyrosine (DIT) is a regulatory ligand for thyroid peroxidase, enzyme, which is involved in the production of thyroxine (T4) and triiodothyronine (T3), the thyroid hormones. Diiodotyrosine was proposed to be a new marker of leukocyte phagocytic activity in sepsis and severe infections.
Status:
Possibly Marketed Outside US
Source:
Alexidine by Chemos GmbH
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Alexidine dihydrochloride, an antibacterial compound, which is used during endodontic procedures. It is a dibiguanide ahent and is effective inhibitor of protein tyrosine phosphatases localized to mitochondrion 1 (PTPMT1). It was noted that PTPMT1 could serve as a pharmacological target in the treatment of type II diabetes. Alexidine dihydrochloride is also an apoptosis-promoting agent possessing the anticancer properties.
Status:
US Approved Rx
(1986)
Source:
NDA019492
(1986)
Source URL:
First approved in 1971
Source:
FREAMINE 8.5% by B BRAUN
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT04562766: Phase 3 Interventional Active, not recruiting Immune Thrombocytopenia
(2020)
Source URL:
Class:
MIXTURE
